Reata Pharmaceuticals Statistics
Share Statistics
Reata Pharmaceuticals has 38.1M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 38.1M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 680 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 2.39M, so 6.28% of the outstanding
shares have been sold short.
| Short Interest | 2.39M |
| Short % of Shares Out | 6.28% |
| Short % of Float | 8.14% |
| Short Ratio (days to cover) | 3.09 |
Valuation Ratios
The PE ratio is -4.42 and the forward
PE ratio is null.
Reata Pharmaceuticals's PEG ratio is
-0.91.
| PE Ratio | -4.42 |
| Forward PE | n/a |
| PS Ratio | 622.68 |
| Forward PS | n/a |
| PB Ratio | -21 |
| P/FCF Ratio | -6.65 |
| PEG Ratio | -0.91 |
Financial Ratio HistoryEnterprise Valuation
Reata Pharmaceuticals has an Enterprise Value (EV) of 1.46B.
| EV / Sales | 657.49 |
| EV / EBITDA | -5.42 |
| EV / EBIT | -7.13 |
| EV / FCF | -7.02 |
Financial Position
The company has a current ratio of 6.75,
with a Debt / Equity ratio of -1.82.
| Current Ratio | 6.75 |
| Quick Ratio | 6.75 |
| Debt / Equity | -1.82 |
| Debt / EBITDA | -0.44 |
| Debt / FCF | -0.58 |
| Interest Coverage | -6.47 |
Financial Efficiency
Return on Equity is 474.77% and Return on Invested Capital is -502.4%.
| Return on Equity | 474.77% |
| Return on Assets | -60.62% |
| Return on Invested Capital | -502.4% |
| Revenue Per Employee | $6,903.43 |
| Profits Per Employee | $-971,654.21 |
| Employee Count | 321 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -25K |
| Effective Tax Rate | 0.01% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 1.42, so Reata Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.42 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 159.77 |
| 200-Day Moving Average | 95.71 |
| Relative Strength Index (RSI) | 84.69 |
| Average Volume (20 Days) | 954,093 |
Income Statement
In the last 12 months, Reata Pharmaceuticals had revenue of 2.22M
and earned -311.9M
in profits. Earnings per share was -8.59.
| Revenue | 2.22M |
| Gross Profit | 2.22M |
| Operating Income | -270.15M |
| Net Income | -311.9M |
| EBITDA | -269.02M |
| EBIT | -270.15M |
| Earnings Per Share (EPS) | -8.59 |
Full Income StatementBalance Sheet
The company has 42.31M in cash and 119.46M in
debt, giving a net cash position of -77.15M.
| Cash & Cash Equivalents | 42.31M |
| Total Debt | 119.46M |
| Net Cash | -77.15M |
| Retained Earnings | -1.57B |
| Total Assets | 502.59M |
| Working Capital | 276.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -204.27M
and capital expenditures -3.27M, giving a free cash flow of -207.54M.
| Operating Cash Flow | -204.27M |
| Capital Expenditures | -3.27M |
| Free Cash Flow | -207.54M |
| FCF Per Share | -5.71 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -12191.11% and -14074.95%.
| Gross Margin | 100% |
| Operating Margin | -12191.11% |
| Pretax Margin | -14076.08% |
| Profit Margin | -14074.95% |
| EBITDA Margin | -12140.12% |
| EBIT Margin | -12191.11% |
| FCF Margin | -9365.39% |
